高级检索
当前位置: 首页 > 详情页

Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ Fourth Hosp, Dept Radiat Oncol 1, Shijiazhuang 050011, Peoples R China [2]Beijing Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China [3]N China Petr Bur Gen Hosp, Dept Oncol, Renqiu 062552, Peoples R China [4]Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Radiol, Okayama 7008558, Japan
出处:
ISSN:

关键词: esophageal neoplasm concurrent chemoradiotherapy cisplatin 5-fluorouracil dose escalation

摘要:
We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m(2) on day 1, and 5-FU 500 mg/m(2) on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m(2) with 5-FU 700 mg/m(2) and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m(2) with 5-FU 700 mg/m(2) and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m(2) on day 1 and 5FU 700 mg/m(2) on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2008]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2008]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2008版] 出版当年五年平均 出版前一年[2007版] 出版后一年[2009版]

第一作者:
第一作者机构: [1]Hebei Med Univ Fourth Hosp, Dept Radiat Oncol 1, Shijiazhuang 050011, Peoples R China [3]N China Petr Bur Gen Hosp, Dept Oncol, Renqiu 062552, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ Fourth Hosp, Dept Radiat Oncol 1, Shijiazhuang 050011, Peoples R China [2]Beijing Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42314 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号